Literature DB >> 16875983

p38 mitogen-activated protein kinase: a future target for heart failure therapy?

Risto Kerkela, Thomas Force.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16875983     DOI： 10.1016/j.jacc.2006.05.005

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN： 0735-1097            Impact factor:   24.094


× No keyword cloud information.
  20 in total

Review 1.  Mitogen-activated protein kinases in heart development and diseases.

Authors:  Yibin Wang
Journal:  Circulation       Date:  2007-09-18       Impact factor: 29.690

2.  MMI-0100 inhibits cardiac fibrosis in myocardial infarction by direct actions on cardiomyocytes and fibroblasts via MK2 inhibition.

Authors:  Lei Xu; Cecelia C Yates; Pamela Lockyer; Liang Xie; Ariana Bevilacqua; Jun He; Cynthia Lander; Cam Patterson; Monte Willis
Journal:  J Mol Cell Cardiol       Date:  2014-10-01       Impact factor: 5.000

3.  Biomechanical defects and rescue of cardiomyocytes expressing pathologic nuclear lamins.

Authors:  Erik Laurini; Valentina Martinelli; Thomas Lanzicher; Luca Puzzi; Daniele Borin; Suet Nee Chen; Carlin S Long; Patrice Lee; Luisa Mestroni; Matthew R G Taylor; Orfeo Sbaizero; Sabrina Pricl
Journal:  Cardiovasc Res       Date:  2018-05-01       Impact factor: 10.787

4.  Effect of pressure overload-induced hypertrophy on the expression and localization of p38 MAP kinase isoforms in the mouse heart.

Authors:  Dharmendra Dingar; Clémence Merlen; Scott Grandy; Marc-Antoine Gillis; Louis R Villeneuve; Aida M Mamarbachi; Céline Fiset; Bruce G Allen
Journal:  Cell Signal       Date:  2010-06-17       Impact factor: 4.315

Review 5.  The p38 mitogen-activated protein kinase pathway--a potential target for intervention in infarction, hypertrophy, and heart failure.

Authors:  Michael S Marber; Beth Rose; Yibin Wang
Journal:  J Mol Cell Cardiol       Date:  2010-11-06       Impact factor: 5.000

6.  p38α regulates SERCA2a function.

Authors:  Leena Kaikkonen; Johanna Magga; Veli-Pekka Ronkainen; Elina Koivisto; Ábel Perjes; J Kurt Chuprun; Leif Erik Vinge; Teemu Kilpiö; Jani Aro; Johanna Ulvila; Tarja Alakoski; James A Bibb; Istvan Szokodi; Walter J Koch; Heikki Ruskoaho; Risto Kerkelä
Journal:  J Mol Cell Cardiol       Date:  2013-12-17       Impact factor: 5.000

7.  Common variants associated with changes in levels of circulating free fatty acids after administration of glucose-insulin-potassium (GIK) therapy in the IMMEDIATE trial.

Authors:  K L Ellis; Y Zhou; L Rodriguez-Murillo; J R Beshansky; E Ainehsazan; H P Selker; G S Huggins; L A Cupples; I Peter
Journal:  Pharmacogenomics J       Date:  2015-12-08       Impact factor: 3.550

8.  Effects of Wenyangzhenshuai Granule on ERK1/2 and ERK5 activity in the myocardial tissue in a rabbit model of adriamycin-induced chronic heart failure.

Authors:  Xinyu Chen; Huzhi Cai; Qingyang Chen; Haibo Xie; Yuemei Liu; Qing Lu; Yanping Tang
Journal:  Int J Clin Exp Med       Date:  2015-11-15

9.  Requirement for p38 mitogen-activated protein kinase activity in neointima formation after vascular injury.

Authors:  Brandon M Proctor; Xiaohua Jin; Traian S Lupu; Louis J Muglia; Clay F Semenkovich; Anthony J Muslin
Journal:  Circulation       Date:  2008-07-21       Impact factor: 29.690

10.  Improved heart failure by Rhein lysinate is associated with p38MAPK pathway.

Authors:  Wei Wang; Xin Meng; Jing Wang; Yong Li
Journal:  Exp Ther Med       Date:  2018-07-09       Impact factor: 2.447
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.